This session examines how advanced technologies are reshaping clinical trials as artificial intelligence (AI), machine learning (ML), and digital health tools become embedded across the drug development life cycle - from trial design and patient selection to endpoint assessment and regulatory decision-making.

The session will share case examples leveraging predictive models, wearable-derived endpoints, and real-world data.

The session will provide a concise roadmap for deploying AI and digital tools responsibly, recognizing common pitfalls, and navigating the evolving regulatory landscape that is redefining the future of quantitative science in drug development.